Clinical trials
Liver Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting liver cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,775 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05318469RecruitingPhase 1/Phase 2
Ivermectin with immunotherapy for metastatic triple-negative breast cancer
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
Los Angeles, CaliforniaAges 18 years+ - NCT05267912Recruiting
Using tumor organoids to guide treatment for advanced cancers
This study tests whether growing a patient's tumor cells in a dish (called an organoid) can help doctors choose the best next treatment. It is for people with advanced colorectal or pancreatic cancer who have run out of standard options.
Bordeaux, FranceAges 18 years+ - NCT05276310RecruitingPhase 1
Study of IMC-002 in advanced cancer
This study tests a new drug called IMC-002 in people with advanced cancer that has not responded to standard treatment. It aims to see if the drug is safe and effective, and may be given alone or with other treatments depending on the cancer type.
Goyang-siAges 19 years+ - NCT05178472Recruiting
Spine radiation plus cement procedure for spine metastasis
This study looks at whether treating certain spine tumors with a cement procedure (vertebroplasty) plus focused radiation can control the cancer and improve quality of life. It is for adults with spine metastases that are not clearly defined and meet specific stability and imaging needs.
Columbus, OhioAges 18 years+ - NCT05112991RecruitingPhase 2
Check whether envafolimab plus lenvatinib helps advanced uterine cancer
This Phase 2 trial tests whether envafolimab alone or combined with lenvatinib can slow or shrink advanced endometrial (uterine) cancer. It’s for people whose cancer has grown again or spread and who didn’t do well with standard platinum chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05099172RecruitingPhase 1/Phase 2
Targeted therapy for advanced lung cancer with EGFR or HER2 changes
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
Gilbert, ArizonaAges 18 years+ - NCT05085496RecruitingPhase 1
Radiation plus atezolizumab for advanced skin cancer
This Phase 1 trial studies adding atezolizumab (an immune therapy) to radiation for people with hard-to-remove or borderline-resectable cutaneous squamous cell carcinoma (cSCC). The goal is to see whether this combination can better control the cancer and whether the treatment is safe.
Duarte, CaliforniaAges 18 years+ - NCT05010031RecruitingPhase 2
Lower-dose radiation for metastatic cancer with an ATM mutation
This trial tests whether giving a lower dose of radiation can help control metastatic tumors that carry a specific genetic change in the ATM gene. It may reduce side effects by using less radiation, while still aiming to keep the tumor under control.
Basking Ridge, New JerseyAges 18 years+ - NCT04929223RecruitingPhase 1
Targeted drug study for metastatic colon or rectal cancer
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
Birmingham, AlabamaAges 18 years+ - NCT04986423RecruitingPhase 2
Add ZEN003694 to enzalutamide for resistant prostate cancer
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
Los Angeles, CaliforniaAges 18 years+ - NCT04983095Recruiting
Targeted radiation for a few prostate cancer metastases
This trial looks at whether a precise form of radiation (stereotactic body radiotherapy) can control a small number of prostate cancer spots seen on a special scan (PSMA PET/CT). It may help by treating limited metastases while avoiding unnecessary treatment elsewhere.
Lund, LundAges 18 years+ - NCT04989725RecruitingPhase 2
Precision radiation for a few new cancer spots while on treatment
This trial tests a precise, high-dose radiation technique (SABR) for people whose cancer has started to grow again in only a few spots despite ongoing medication. The goal is to control those new growths while continuing your current treatment.
Montreal, QuebecAges 18 years+ - NCT04997993RecruitingPhase 1
Leflunomide for PTEN-altered or HER2-negative metastatic cancers
This Phase 1 trial studies whether leflunomide can slow or control advanced (metastatic) cancers in people whose tumors have specific PTEN changes or who have HER2-negative breast cancer. It’s primarily a safety-and-dosing study, but it may offer benefit if your cancer matches the tumor marker requirements.
New York, New YorkAges 18 years+ - NCT04916613RecruitingPhase 3
ADT plus darolutamide for vulnerable newly metastatic prostate cancer
This trial studies whether adding darolutamide to standard hormone therapy (ADT) helps men with newly diagnosed metastatic prostate cancer who are physically vulnerable. It aims to control the cancer better while checking safety and how well treatment is tolerated in this group.
CharleroiAges 18 years+ - NCT04689347RecruitingPhase 1/Phase 2
New chemotherapy and targeted drug for a specific colon cancer type
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
Milan, MilanAges 18–75 - NCT04704505RecruitingPhase 2
Testosterone-like treatment plus radium for bone-spread prostate cancer
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
Baltimore, MarylandAges 18 years+ - NCT04614103RecruitingPhase 2
Immune cell therapy for advanced lung cancer after chemotherapy
This trial studies LN-145, a treatment made from your own immune cells, for metastatic (stage IV) non-small-cell lung cancer. It may help shrink tumors after your cancer has progressed despite standard first-line chemotherapy and immunotherapy.
Gilbert, ArizonaAges 18–70 - NCT04680715RecruitingPhase 2
Tested radiation before and after breast surgery in older women
This Phase 2 trial looks at a specific radiation timing and technique around the time of breast-conserving surgery. It may help reduce the chance the cancer comes back in selected older patients with certain early-stage, hormone-positive, HER2-negative breast cancers.
Clermont-FerrandAges 65 years+ - NCT04491929Recruiting
Radiation treatment for colon cancer in the liver using tiny beads
This trial studies a targeted liver radiation procedure that uses tiny radioactive beads to treat colon cancer spread mostly in the liver. It may help people whose liver tumors cannot be removed or treated with other common local treatments, but it has several safety and “screening” checks.
Aarhus N, DanmarkAges 18 years+ - NCT04068649RecruitingPhase 2
Single high-dose radiation vs standard palliative radiation
This Phase 2 study compares a one-time, high-dose radiation treatment (SBRT) with the usual, shorter-course palliative radiation. The goal is to see which approach better relieves symptoms from metastatic (spread) cancer.
Buffalo, New YorkAges 18 years+ - NCT03972657RecruitingPhase 1/Phase 2
Testing a new prostate and kidney cancer drug with immunotherapy
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Gilbert, ArizonaAges 18 years+ - NCT03275311Recruiting
Care approach changes for metastatic breast cancer
This trial looks at how treatment care for metastatic breast cancer has evolved over time. You may be eligible if you are an adult receiving active cancer treatment in a comprehensive cancer center in France.
AngersAges 18 years+ - NCT07814248RecruitingPhase 1
TS-104 for advanced solid tumors
This trial tests a new drug called TS-104 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is given alone (not with other cancer treatments) to see if it can shrink tumors or slow their growth.
Maumee, OhioAges 18 years+ - NCT07625644RecruitingPhase 3
New immunotherapy combination for advanced lung cancer
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
Springdale, ArkansasAges 18 years+
Hear when a new Liver Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,775 recruiting liver cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Locally Advanced or Metastatic)
- Locally Advanced Rectal Cancer
- Locally Advanced Cervical Cancer
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.